Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

Accelerated approval for glioblastoma multiforme can be based on objective response rate, panel tells FDA.
Advertisement

Related Content

Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma
Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS069209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel